Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EViSCO trial of valaciclovir for Epstein-Barr virus suppression in COPD
2017-004686-28Phase 2Terminated
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Jun 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valaciclovir in Epstein-Barr virus infection, chronic obstructive pulmonary disease (COPD), sponsored by Belfast Health and Social Care Trust. Started Jun 2019; status: terminated.
02
Drugs
valaciclovir
03
Conditions
Epstein-Barr virus infectionchronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-004686-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004686-28.